Genomic Fusions in Pigmented Spindle Cell Nevus of Reed

Recent molecular studies of spitzoid neoplasms have identified mutually exclusive kinase fusions involving ROS1, ALK, RET, BRAF, NTRK1, MET, and NTRK3 as early initiating genomic events. Pigmented spindle cell nevus (PSCN) of Reed is a morphologic variant of Spitz and may be very diagnostically challenging, having histologic features concerning for melanoma. Their occurrence in younger patients, lack of association to sun exposure, and rapid early growth phase similar to Spitz nevi suggest fusions may also play a significant role in these lesions. However, to date, there is little data in the literature focused on the molecular characterization of PSCN of Reed with next-generation sequencing. We analyzed a total of 129 melanocytic neoplasms with RNA sequencing including 67 spitzoid neoplasms (10 Spitz nevi, 44 atypical Spitz tumors, 13 spitzoid melanomas) and 23 PSCN of Reed. Although only 2 of 67 (3.0%) of spitzoid lesions had NTRK3 fusions, 13 of 23 (57%) of PSCN of Reed harbored NTRK3 fusions with 5′ partners ETV6 (12p13) in 2 cases and MYO5A (15q21) in 11 cases. NTRK3 fusions were confirmed with a fluorescent in situ hybridization break-apart probe. The presence of a NTRK3 fusion correlated with younger age (P=0.021) and adnexal extension (P=0.001). Other minor fusions identified in PSCN of Reed included MYO5A-MERTK (2), MYO5A-ROS1, MYO5A-RET, and ETV6-PITX3 leading to a total of 78% with fusions. Our study suggests that the majority of PSCN of Reed are the result of genomic fusions, and the most frequent and characteristic genomic aberration is an NTRK3 fusion.

[1]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[2]  C. Genoud,et al.  mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition , 2017, Oncotarget.

[3]  M. Ladanyi,et al.  Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms. , 2017, The Journal of molecular diagnostics : JMD.

[4]  Pedram Gerami,et al.  A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms , 2017, The American journal of surgical pathology.

[5]  A. Drilon,et al.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.

[6]  L. Gong,et al.  Genetic analysis of PITX3 variants in patients with essential tremor , 2017, Acta neurologica Scandinavica.

[7]  G. Kristiansen,et al.  PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma , 2017, Clinical Epigenetics.

[8]  I. Yeh,et al.  NTRK3 kinase fusions in Spitz tumours , 2016, The Journal of pathology.

[9]  G. Kristiansen,et al.  PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy , 2016, Clinical Epigenetics.

[10]  A. Pappo,et al.  Infantile Fibrosarcoma With NTRK3–ETV6 Fusion Successfully Treated With the Tropomyosin‐Related Kinase Inhibitor LOXO‐101 , 2016, Pediatric blood & cancer.

[11]  K. Busam,et al.  Spitz Tumors , 2016, International journal of surgical pathology.

[12]  J. Easton,et al.  The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing , 2016, Modern Pathology.

[13]  I. Yeh,et al.  Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions , 2015, The American journal of surgical pathology.

[14]  I. Yeh,et al.  Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors , 2015, Nature Communications.

[15]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[16]  E. Sviderskaya,et al.  Myosin-Va and Dynamic Actin Oppose Microtubules to Drive Long-Range Organelle Transport , 2014, Current Biology.

[17]  S. Almo,et al.  Overexpression of MERTK Receptor Tyrosine Kinase in Epithelial Cancer Cells Drives Efferocytosis in a Gain-of-Function Capacity* , 2014, The Journal of Biological Chemistry.

[18]  L. Cerroni,et al.  Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors With ALK Fusions , 2014, The American journal of surgical pathology.

[19]  B. B. Weitner,et al.  Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up , 2014, The American journal of surgical pathology.

[20]  J. Drouin,et al.  Redox regulation by Pitx2 and Pitx3 is critical for fetal myogenesis. , 2014, Developmental Cell.

[21]  M. Nikiforova,et al.  ETV6‐NTRK3 is a common chromosomal rearrangement in radiation‐associated thyroid cancer , 2014, Cancer.

[22]  A. Pierce,et al.  MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme , 2014, Oncotarget.

[23]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[24]  F. Jiménez-Jiménez,et al.  PITX3 and Risk for Parkinson's Disease: A Systematic Review and Meta-Analysis , 2013, European Neurology.

[25]  T. Boggon,et al.  MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL , 2013, Pigment cell & melanoma research.

[26]  C. Miller,et al.  MERTK receptor tyrosine kinase is a therapeutic target in melanoma. , 2013, The Journal of clinical investigation.

[27]  A. Merlo,et al.  Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme , 2013, Oncogene.

[28]  W. Franklin,et al.  Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer , 2012, Oncogene.

[29]  S. Tavazoie,et al.  A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells , 2011, Nature.

[30]  John A. Hammer,et al.  Walking to work: roles for class V myosins as cargo transporters , 2011, Nature Reviews Molecular Cell Biology.

[31]  J. Malvehy,et al.  Pigmented Spindle Cell Nevus: Clues for Differentiating It From Spindle Cell Malignant Melanoma. A Comprehensive Survey Including Clinicopathologic, Immunohistochemical, and FISH Studies , 2011, The American journal of surgical pathology.

[32]  A. Thorburn,et al.  Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity , 2010, Molecular Cancer Therapeutics.

[33]  B. Perez-Ordonez,et al.  Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity , 2010, The American journal of surgical pathology.

[34]  J. Foekens,et al.  DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy , 2009, Clinical Cancer Research.

[35]  L. French,et al.  Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. , 2008, The Journal of investigative dermatology.

[36]  L. Meltesen,et al.  Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase , 2006, Oncogene.

[37]  P. Sorensen,et al.  ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. , 2005, Seminars in cancer biology.

[38]  H. Kung,et al.  Signal Pathways in Up-regulation of Chemokines by Tyrosine Kinase MER/NYK in Prostate Cancer Cells , 2004, Cancer Research.

[39]  M. Cook.  Benign melanocytic lesions mimicking melanomas. , 2004, Pathology.

[40]  P. Sorensen,et al.  A Highly Conserved NTRK3 C-terminal Sequence in the ETV6-NTRK3 Oncoprotein Binds the Phosphotyrosine Binding Domain of Insulin Receptor Substrate-1 , 2004, Journal of Biological Chemistry.

[41]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[42]  R. Scott,et al.  Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.

[43]  David R Kaplan,et al.  Neurotrophin signal transduction in the nervous system , 2000, Current Opinion in Neurobiology.

[44]  P. Sorensen,et al.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells , 2000, Oncogene.

[45]  P. Sorensen,et al.  ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. , 1998, Cancer research.

[46]  Y Fujiwara,et al.  The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. , 1998, Genes & development.

[47]  P. Sorensen,et al.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.

[48]  L. Requena,et al.  Pigmented spindle cell naevus , 1990, The British journal of dermatology.

[49]  M. Mihm,et al.  Pigmented spindle cell naevus and its variants: distinction from melanoma , 1989, The British journal of dermatology.

[50]  W. Clark,et al.  Common and uncommon melanocytic nevi and borderline melanomas. , 1975, Seminars in oncology.

[51]  H. Earp,et al.  Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer , 2013 .

[52]  J. Nichols,et al.  Homeodomain protein Pitx3 maintains the mitotic activity of lens epithelial cells , 2009, Mechanisms of Development.